CAI

Caris Life Sciences, Inc.

Nasdaq· Services-Medical Laboratories· Inc. TX· CIK 0002019410 Healthcare & Medical Devices

$33.29 +0.84 (+2.59%)

Oct 27 4:00 PM ET · prev $32.46

Market cap

$9.0B

Mid cap

Consensus

Buy

75% Buy or better · 16 analysts

Median target

$33.00

−1% · range $22.00–38.00

Next earnings

Nov 4

in 8 days

1 year

+10.1%

from $30.25 · Oct 27

30 days

+4.9%

from $31.75

52-week range

$14.55–33.29

at the high

Avg volume 20D

3.47M

shares / day

Short interest

🔒 Subscribers only

Insider net

−$25.7M

2 buyers · 3 sellers · 12 mo

New fund stakes

Q2 2026 13F · 1 exit

Filing reports

analyzed by SecBot

SecBot read MIXED 5 reports · 90 days

Balance 2 bearish · 1 bullish · 2 neutral oldest → newest, height = score

Avg score

·High conf. 3/5 ·Next Earnings date, Nov 4, 2026

Strongest BULLISH Three asset managers significantly increased their positions in Caris Life Sciences during Q3 2026, with…

All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

B May 11 to May 15 2 days of insider buys: $1.5M by 2 insiders, avg $15.06
X Jul 31 Short interest jumps 25.8% to 14.76M
S Sep 3 to Sep 4 2 days of insider sells: $14.8M by 1 insider, avg $24.84
A Sep 9 UBS initiates
S Sep 17 to Sep 22 2 days of insider sells: $12.4M by 2 insiders, avg $30.36
R Sep 23 Two Caris Life Sciences insiders, including CEO Brian Brille, sold a…

Signal stack

Where each data set points today.

InsidersBEARISH

2 insiders bought $1.5M at an average $15.06. 3 insiders sold $27.2M. Price is 121% above their cost.
InstitutionsBULLISH

Q2 2026: 50 added (1 new), 15 trimmed or exited. Largest new: Hrt Financial $25.3M.
AnalystsBULLISH

12 of 16 rate it Buy or better. Median target $33.00 (−1%).
TrendUPTREND

17% above its 50-day average. New closing high $33.29 on Oct 27.

Who's buying

13F· Q2 2026

new positions

exit

$25.3M

in new stakes

Fund	Move	Shares	Value
JPMORGAN CHASE & CO	ADD	6,558,514	$120.2M
VANGUARD PORTFOLIO MANAGEMENT LLC	ADD	4,844,431	$86.3M
VANGUARD CAPITAL MANAGEMENT LLC	ADD	4,280,238	$76.3M
LOS ANGELES CAPITAL MANAGEMENT LLC	ADD	3,958,531	$70.5M
BNP PARIBAS FINANCIAL MARKETS	ADD	2,370,268	$42.2M
MILLENNIUM MANAGEMENT LLC	ADD	2,202,647	$39.3M
MORGAN STANLEY	ADD	1,935,531	$34.5M
UBS Group AG	TRIM	1,423,371	$25.4M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

16 analysts

Buy 75% rate it Buy or better

Strong Buy6Buy6Hold4Sell0Strong Sell0

12-month targets · 13 analysts

$33.29 $22.00 $33.00 $38.00

Price is inside the target range. Median implies −1%.Targets as of Oct 27, 2026.

Recent actions

Date	Firm	Action	Rating
Oct 19, 2026	Canaccord Genuity MAINTAIN	MAINTAIN	Hold
Oct 14, 2026	JP Morgan MAINTAIN	MAINTAIN	Overweight
Oct 13, 2026	TD Cowen MAINTAIN	MAINTAIN	Buy
Sep 9, 2026	UBS INITIATE	INITIATE	Neutral
Aug 6, 2026	Evercore ISI Group MAINTAIN	MAINTAIN	Outperform
Aug 6, 2026	BTIG MAINTAIN	MAINTAIN	Buy

Insider ledger

Form 4

$1.5M

bought · 2 insiders

$27.2M

sold · 3 insiders

+121.1%

vs their $15.06 cost

Date	Insider	Type	Value
Sep 22, 2026	Denton John Russel See Remarks	SELL	$238.6K
Sep 17, 2026	Brille Brian J See Remarks	EXERCISE	$976.0K
Sep 17, 2026	Brille Brian J See Remarks	SELL	$12.1M
Sep 4, 2026	Spetzler David Baxley President	EXERCISE	$610.0K
Sep 4, 2026	Spetzler David Baxley President	SELL	$3.0M
Sep 3, 2026	Spetzler David Baxley President	SELL	$2.1M
Sep 3, 2026	Spetzler David Baxley President	SELL	$9.7M
Sep 3, 2026	Spetzler David Baxley President	EXERCISE	$2.4M

Earnings setup

Estimates

Nov 4

reports in 8 days

Revision history: 🔒 Fresh data, subscribers only

Period	EPS est.	Range	30D rev.	Revenue
Current Q	🔒 Fresh data, subscribers only
Next Q	🔒 Fresh data, subscribers only
Current FY	🔒 Fresh data, subscribers only
Next FY	🔒 Fresh data, subscribers only

Washington

Corporate Lobbying

10 lobbying filings and 3 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Short side

FINRA· Oct 15, 2026

🔒 Subscribers only

shares short

Recent activity

The latest filings, insider trades, analyst actions, press and options flow — newest first.

Oct 20, 2026 SEC

Three asset managers significantly increased their positions in Caris Life Sciences during Q3 2026, with aggregate…

INST-CLUSTER — Impact 4/10

Oct 19, 2026 Other

Caris Life Sciences Launches New National Commercial Featuring Jordan Spieth Highlighting the Power of Artificial Intelligence in Early Stage Cancer Detection

New campaign connects AI-powered performance insights linking advanced molecular intelligence to hel

Oct 15, 2026 SEC

Caris Life Sciences announced it will report its Q3 2026 results on November 4, 2026.

PRESS-RELEASE — Impact 1/10

Sep 23, 2026 SEC

Two Caris Life Sciences insiders, including CEO Brian Brille, sold a total of $12.37M in shares within a week…

CLUSTER — Impact 6/10

Sep 22, 2026 Insider

Denton John Russel sold 7,500 shares

See Remarks @ $31.82 ($238.6K)

Sep 17, 2026 Insider

Brille Brian J acquired via exercise 400,000 shares

See Remarks @ $2.44 ($976.0K)

Sep 17, 2026 Insider

Brille Brian J sold 400,000 shares

See Remarks @ $30.33 ($12.1M)

Jun 30, 2026 Inst.

JPMORGAN CHASE & CO — ADD

6,558,514 shares ($120.2M)

Catalysts

Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.

Upcoming

Nov 4, 2026

Earnings date

CAI Q3 2026 Earnings Scheduled — 2026-11-04

Recent

Oct 19, 2026

Press release

Caris Life Sciences Launches New National Commercial Featuring Jordan Spieth Highlighting the Power of Artificial Intelligence in Early Stage Cancer Detection

New campaign connects AI-powered performance insights linking advanced molecular intelligence to help detect cancer in earlier stages IRVING, Texas…

Oct 15, 2026

Earnings

Caris Life Sciences to Report Third Quarter 2026 Financial Results on November 4, 2026

IRVING, Texas, Oct. 15, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading TechBio company, today announced it will report third…

Oct 14, 2026

Press release

Caris Life Sciences to Present Eight Studies Highlighting the Power of AI, Multi-Omics and Precision Medicine at ESMO 2026

Eight posters will feature AI-driven approaches to treatment prediction, risk stratification and biomarker discovery advancing precision medicine…

Sep 8, 2026

Press release

Caris Life Sciences Launches New National Commercial Featuring Kevin Costner to Raise Awareness of Early Cancer Detection and Caris Detect

New partnership highlights the importance of finding cancer earlier through Caris Detect, a multi-cancer early detection blood test now available…

Aug 5, 2026

Earnings date

CAI Q2 2026 Earnings Scheduled — 2026-08-05

SecBot reports

8 filings · 2 bullish · 2 bearish · 4 neutral

All CAI filing & press-release reports (8)

INST-CLUSTER reportOct 20, 2026
PRESS-RELEASE reportOct 15, 2026
CLUSTER reportSep 23, 2026
8-K reportSep 14, 2026
144 reportAug 7, 2026
CLUSTER reportJul 13, 2026
INST-CLUSTER reportJun 11, 2026
DEFA14A reportApr 23, 2026